Gabapentin is available as a generic medication. The U.S. Food and Drug Administration (FDA) approved the first generic version of gabapentin in 2000 [1].
When did gabapentin go off patent?
The patent for the original brand-name gabapentin, Neurontin, expired in 2000, allowing generic manufacturers to produce and market their own versions of the drug [1].
Who manufactures generic gabapentin?
Multiple pharmaceutical companies produce generic gabapentin. These manufacturers include Teva Pharmaceuticals, Mylan N.V., and Sun Pharmaceutical Industries, among others [2].
What are the benefits of generic gabapentin?
Generic gabapentin offers a significant cost advantage compared to the brand-name version. Patients and healthcare systems benefit from lower drug expenses, making treatment more accessible. Generic medications are required to meet the same FDA standards for safety, efficacy, and quality as their brand-name counterparts [3].
How does generic gabapentin compare to brand-name Neurontin?
Generic gabapentin is bioequivalent to brand-name Neurontin, meaning it has the same active ingredient, dosage form, strength, and route of administration [3]. The FDA requires generic drugs to perform in the same way as the brand-name drug in the body. Any differences in inactive ingredients, such as dyes or fillers, do not affect the drug's performance or safety [3].
What conditions is generic gabapentin used to treat?
Generic gabapentin is prescribed to manage partial seizures in adults and children and to relieve nerve pain following shingles (postherpetic neuralgia) [4].
Where can I find information on gabapentin patents?
Information on drug patents, including those for gabapentin and its generic versions, can be found on DrugPatentWatch.com. This resource tracks patent expiry dates and exclusivity periods for pharmaceuticals [5].
Sources:
1. https://www.drugpatentwatch.com/drug/gabapentin
2. https://www.goodrx.com/gabapentin
3. https://www.fda.gov/drugs/generic-drugs/questions-and-answers-generics
4. https://www.ncbi.nlm.nih.gov/books/NBK542170/
5. https://www.drugpatentwatch.com/